Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Gabrielle Cerda

Psychiatry San Diego, CA Medical Doctor

NPI 1407887748 CMS profile 290977

1809 National Ave, San Diego, CA 92113

Open in the dashboard

General payments

$4,857

220 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Gabrielle Cerda of San Diego, CA is reported in the CMS Open Payments database as having received $4,857 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,176 47
2023 General $1,689 75
2022 General $1,060 52
2021 General $142 7
2020 General $182 5
2019 General $609 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gabrielle Cerda
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Gabrielle Cerda were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Gabrielle Cerda Psychiatry median Middle half National median
2019 $609 $184 $59–$605 $163
2020 $182 $119 $36–$372 $114
2021 $142 $143 $43–$576 $132
2022 $1,060 $153 $50–$590 $149
2023 $1,689 $170 $56–$651 $160
2024 $1,176 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. ITI, Inc. $1,084 60 payments
  2. Alkermes, Inc. $982 34 payments
  3. Janssen Pharmaceuticals, Inc $827 42 payments
  4. Otsuka America Pharmaceutical, Inc. $686 27 payments
  5. Neurocrine Biosciences, Inc. $386 17 payments
  6. Teva Pharmaceuticals USA, Inc. $385 19 payments
  7. AbbVie, Inc. $217 9 payments
  8. Indivior Inc. $155 6 payments
  9. Lundbeck LLC $99 5 payments
  10. Janssen Scientific Affairs, LLC $36 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $4,792 216 payments
  2. Education $66 4 payments
Products named General payments · program years 2019–2024
  1. CAPLYTA $1,084 60 payments
  2. ARISTADA Cns $726 29 payments
  3. ARISTADA Cns $726 29 payments
  4. INVEGA SUSTENNA $700 31 payments
  5. ARISTADA Cns $609 23 payments
  6. ARISTADA Cns $609 23 payments
  7. LYBALVI $536 20 payments
  8. ABILIFY MAINTENA $472 19 payments
  9. ARISTADA INITIO $401 16 payments
  10. REXULTI $389 17 payments
  11. Other $2,567 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

2,228

Median for Psychiatry: 574

Drug cost

$891,418

Median for Psychiatry: $27,624

Branded share of claims

23.9%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 85 $264,592
Ingrezza Valbenazine Tosylate Brand 38 $261,534
Austedo Deutetrabenazine Brand 13 $73,727
Caplyta Lumateperone Tosylate Brand 48 $70,533
Abilify Maintena Aripiprazole Brand 19 $54,608
Vraylar Cariprazine Hcl Brand 26 $37,337
Aristada Aripiprazole Lauroxil Brand 16 $37,266
Uzedy Risperidone Brand 17 $36,382
Risperdal Consta Risperidone Microspheres Brand 11 $12,873
Trintellix Vortioxetine Hydrobromide Brand 14 $6,606

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$6,239

Medicare's payments for the services billed

Medicare patients

27

Average age 53

Services billed

95

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Atrial fibrillation 0%
COPD 0%
Cancer 0%
Osteoporosis 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $275
$275 48 —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $185
$185 85 —
INGREZZA
  • Neurocrine Biosciences, Inc. $133
$133 38 —
VIVITROL
  • Alkermes, Inc. $119
$119 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $118
$118 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record